BioCentury
ARTICLE | Clinical News

FDA wants extra trial for Pharming's Ruconest as HAE Prophylactic

September 21, 2018 4:26 PM UTC

Pharming Group N.V. (Euronext:PHARM) said FDA requested another clinical trial of Ruconest conestat alfa as a prophylactic for hereditary angioedema in a complete response letter for an sBLA in the indication.

Pharming, which fell €0.20 (20%) to €0.77 Sept. 19, declined to provide a timeline for a resubmission...

BCIQ Company Profiles

Pharming Group N.V.

BCIQ Target Profiles

Complement 1 (C1) esterase